NetScientific's Glycotest receives second $3 million tranche from Fosun Pharma
Glycotest are currently developing pipeline tests for liver fibrosis and cholangiocarcinoma, the second most prevalent form of liver cancer.
The second tranche will enable Glycotest to advance the clinical validation study for their unique algorithm-driven biomarker panel, HCC, which the company kick-started at multiple major US clinical sites earlier this year.
The focus of this strategic investment is to advance the HCC toward full commercial launch in the United States who have an estimated three million or more at-risk patients for HCC surveillance testing.
Involving over 480 patients, the studies have so far shown the HCC Panel to identify patients with curable early-stage HCC more effectively than the current dominant blood test, AFP.
Additionally, the second tranche will also allow the transfer of the HCC Panel technology to Fosun Pharma's diagnostic subsidiary for commercialization in China, the company revealed.
NSCI price chartUnder the agreement, Fosun Pharma receives a 40% equity stake in Glycotest and a license to manufacture and sell the HCC test in China in return for a royalty on sales to Glycotest.
“Glycotest continues to make excellent progress,” stated Chief Executive of NetScientific, Ian Postlethwaite said Glycostest - “We are proud to be supporters of Glycotest who we believe has the strong potential to deliver value for our shareholders."
Follow News & Updates from NetScientific here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.